Lo Bernard, Padian Nancy, Barnes Mark
Program in Medical Ethics, Center for AIDS Prevention Studies and Division of General Internal Medicine, University of California San Francisco, San Francisco, CA, USA.
AIDS. 2007 Jun 19;21(10):1229-31. doi: 10.1097/QAD.0b013e3281338371.
Providing antiretroviral therapy (ART) to participants who seroconvert during HIV prevention trials in developing countries is an ethical expectation. Promising treatment to the few seroconverters widens disparities within a resource-poor country and would be unjust. Such an assurance should be done in a way that also improves access to ART for others in the country. US funds for ART in poor countries from the PEPFAR should be available to all countries that host HIV prevention and clinical trials.
为在发展中国家进行的艾滋病预防试验中血清转化的参与者提供抗逆转录病毒疗法（ART）是一项道德期望。向少数血清转化者承诺提供治疗会加剧资源匮乏国家内部的差距，而且是不公正的。这种保障措施应以同时改善该国其他人群获得抗逆转录病毒疗法的方式来实施。美国通过总统防治艾滋病紧急救援计划（PEPFAR）为贫穷国家提供的抗逆转录病毒疗法资金应提供给所有开展艾滋病预防和临床试验的国家。
